Keryx Biopharmaceuticals Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of KRX-0401 (Perifosine) Date : 02/03/2010 @ 8:30AM Source : PR Newswire Stock : Keryx Biopharmaceuticals (MM) (KERX) http://ih.advfn.com/p.php?pid=nmona&article=41377888&symbol=KERX